Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Long-term safety of pegloticase in chronic gout refractory to conventional treatment.

Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, Ottery FD, Khanna D, Sundy JS.

Ann Rheum Dis. 2013 Sep 1;72(9):1469-74. doi: 10.1136/annrheumdis-2012-201795. Epub 2012 Nov 10.

2.

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.

Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA.

J Clin Rheumatol. 2014 Dec;20(8):427-32. doi: 10.1097/RHU.0000000000000200. Review.

3.

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA.

JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169.

PMID:
21846852
4.

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA.

Arthritis Res Ther. 2013 Sep 26;15(5):R137. doi: 10.1186/ar4318.

5.

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z; Pegloticase Phase 2 Study Investigators.

Arthritis Rheum. 2008 Sep;58(9):2882-91. doi: 10.1002/art.23810.

6.

Pegloticase: in treatment-refractory chronic gout.

Lyseng-Williamson KA.

Drugs. 2011 Nov 12;71(16):2179-92. doi: 10.2165/11202830-000000000-00000. Review.

PMID:
22035516
7.

Pegloticase for treating refractory chronic gout.

George RL Jr, Sundy JS.

Drugs Today (Barc). 2012 Jul;48(7):441-9. doi: 10.1358/dot.2012.48.7.1813475. Review.

PMID:
22844655
8.

Pegloticase for chronic gout.

Anderson A, Singh JA.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008335. doi: 10.1002/14651858.CD008335.pub2. Review.

PMID:
20238366
9.

Interventions for tophi in gout.

Sriranganathan MK, Vinik O, Bombardier C, Edwards CJ.

Cochrane Database Syst Rev. 2014 Oct 20;(10):CD010069. doi: 10.1002/14651858.CD010069.pub2. Review.

PMID:
25330136
10.

Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.

Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL.

J Rheumatol. 2012 Jul;39(7):1450-7. doi: 10.3899/jrheum.111375. Epub 2012 Jun 1.

11.

Pegloticase: a novel agent for treatment-refractory gout.

Shannon JA, Cole SW.

Ann Pharmacother. 2012 Mar;46(3):368-76. doi: 10.1345/aph.1Q593. Epub 2012 Mar 6. Review.

PMID:
22395256
12.

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.

Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS.

Arthritis Res Ther. 2014 Mar 7;16(2):R63. doi: 10.1186/ar4500.

13.

Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.

Dalbeth N, Doyle AJ, McQueen FM, Sundy J, Baraf HS.

Arthritis Care Res (Hoboken). 2014 Jan;66(1):82-5. doi: 10.1002/acr.22059.

14.

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.

Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA.

Arthritis Res Ther. 2014 Mar 4;16(2):R60. doi: 10.1186/ar4497.

15.

Pegloticase and the patient with treatment-failure gout.

Dave AJ, Kelly VM, Krishnan E.

Expert Rev Clin Pharmacol. 2012 Sep;5(5):501-8. doi: 10.1586/ecp.12.48.

PMID:
23121270
16.

Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.

Bleyer AJ, Wright D, Alcorn H.

Clin Nephrol. 2015 May;83(5):286-92. doi: 10.5414/CN108481.

PMID:
25816806
17.
18.

Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.

Yue CS, Huang W, Alton M, Maroli AN, Waltrip RW, Wright D, Marco MD.

J Clin Pharmacol. 2008 Jun;48(6):708-18. doi: 10.1177/0091270008317589. Epub 2008 Apr 16.

PMID:
18420531
19.

Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.

Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS.

Arthritis Rheum. 2007 Mar;56(3):1021-8. Erratum in: Arthritis Rheum. 2007 Apr;56(4):1370.

20.

Allopurinol for chronic gout.

Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ.

Cochrane Database Syst Rev. 2014 Oct 14;(10):CD006077. doi: 10.1002/14651858.CD006077.pub3. Review.

PMID:
25314636

Supplemental Content

Support Center